Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts

$8.64 -0.21 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$8.64 -0.01 (-0.06%)

As of 06:09 PM Eastern

Karyopharm Therapeutics Earnings Summary

Karyopharm Therapeutics posted Q4 2025 earnings on February 13, 2026, reporting an EPS of -$2.23, which topped analysts' consensus estimates of -$2.26 by $0.03. Quarterly revenue was reported to be $34.08 million, above the consensus estimate of $33.16 million. With a trailing EPS of -$16.62, Karyopharm Therapeutics' earnings are expected to grow next year, from ($4.49) to ($3.78) per share.

Upcoming Earnings Date: May. 11Before Market OpensEstimated
Consensus EPS (Feb. 13): -$2.26
Actual EPS (Feb. 13): -$2.23 Beat By $0.03
Actual Revenue (Feb. 13): $34.08M

Q4 2025 Earnings Resources

KPTI Upcoming Earnings

Karyopharm Therapeutics' Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Slide Deck

Full Screen Slide Deck

Get Karyopharm Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Karyopharm Therapeutics and other key companies, straight to your inbox.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KPTI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KPTI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Karyopharm Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2026	1	-$1.05	-$1.05	-$1.05
Q2 2026	1	-$0.81	-$0.81	-$0.81
Q3 2026	1	-$0.71	-$0.71	-$0.71
Q4 2026	1	-$0.69	-$0.69	-$0.69

Karyopharm Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue	Details
5/11/2026 (Estimated)	-	-	-	-	-	-	-	-
2/13/2026	Q4 2025	-$2.26	-$2.23	+$0.03	-$5.71	$33.16M	$34.08M
11/3/2025	Q3 2025	-$3.30	-$3.82	-$0.52	-$3.82	$39.56M	$44.04M
8/11/2025	Q2 2025	-$3.80	-$4.32	-$0.52	-$4.32	$37.92M	$37.93M
5/12/2025	Q1 2025	-$4.21	-$2.77	+$1.44	-$2.77	$35.12M	$30.02M
2/19/2025	Q4 2024	-$3.90	-$3.60	+$0.30	-$0.24	$30.29M	$30.54M
11/5/2024	Q3 2024	-$4.05	-$3.90	+$0.15	-$0.26	$37.86M	$38.78M
8/6/2024	Q2 2024	-$4.35	-$3.00	+$1.35	-$0.20	$36.07M	$42.79M
5/8/2024	Q1 2024	-$4.95	-$4.80	+$0.15	-$0.32	$35.02M	$33.13M

Data powered by Fiscal.ai.

Karyopharm Therapeutics Earnings - Frequently Asked Questions

Karyopharm Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 11th, 2026 based off last year's report dates. Learn more on KPTI's earnings history.

Karyopharm Therapeutics updated its FY 2026 earnings guidance on Thursday, February, 12th. The company issued revenue guidance of $130.0 million-$150.0 million, compared to the consensus revenue estimate of $145.3 million.

In the previous quarter, Karyopharm Therapeutics (NASDAQ:KPTI) reported ($2.23) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.26) by $0.03. Learn more on analysts' earnings estimate vs. KPTI's actual earnings.

The conference call for Karyopharm Therapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Karyopharm Therapeutics' latest earnings report can be read online.
Read Transcript

Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded annual revenue of $146.07 million.

Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded net income of -$196.04 million. KPTI has generated -$16.62 earnings per share over the last four quarters.

Karyopharm Therapeutics' earnings are expected to grow from ($4.49) per share to ($3.78) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies

Earnings Tools

Latest Articles

This page (NASDAQ:KPTI) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts